4.6 Article

Developing a predictive model for clinically significant prostate cancer by combining age, PSA density, and mpMRI

期刊

WORLD JOURNAL OF SURGICAL ONCOLOGY
卷 21, 期 1, 页码 -

出版社

BMC
DOI: 10.1186/s12957-023-02959-1

关键词

Clinically significant prostate cancer; mpMRI; PI-RADS v2; 1; PSA density; Prostate biopsy; Predictive model

向作者/读者索取更多资源

The study constructed a predictive model for clinically significant prostate cancer (csPCa) and found that the model, which combines age, PSAD, and PI-RADS v2.1 scores, showed excellent clinical efficacy in reducing unnecessary prostate biopsies. The model accurately predicted csPCa and outperformed other predictive factors such as PI-RADS v2.1 scores and PSAD.
PurposeThe study aimed to construct a predictive model for clinically significant prostate cancer (csPCa) and investigate its clinical efficacy to reduce unnecessary prostate biopsies.MethodsA total of 847 patients from institute 1 were included in cohort 1 for model development. Cohort 2 included a total of 208 patients from institute 2 for external validation of the model. The data obtained were used for retrospective analysis. The results of magnetic resonance imaging were obtained using Prostate Imaging Reporting and Data System version 2.1 (PI-RADS v2.1). Univariate and multivariate analyses were performed to determine significant predictors of csPCa. The diagnostic performances were compared using the receiver operating characteristic (ROC) curve and decision curve analyses.ResultsAge, prostate-specific antigen density (PSAD), and PI-RADS v2.1 scores were used as predictors of the model. In the development cohort, the areas under the ROC curve (AUC) for csPCa about age, PSAD, PI-RADS v2.1 scores, and the model were 0.675, 0.823, 0.875, and 0.938, respectively. In the external validation cohort, the AUC values predicted by the four were 0.619, 0.811, 0.863, and 0.914, respectively. Decision curve analysis revealed that the clear net benefit of the model was higher than PI-RADS v2.1 scores and PSAD. The model significantly reduced unnecessary prostate biopsies within the risk threshold of > 10%.ConclusionsIn both internal and external validation, the model constructed by combining age, PSAD, and PI-RADS v2.1 scores exhibited excellent clinical efficacy and can be utilized to reduce unnecessary prostate biopsies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据